Mattia Basile

Dr. Mattia Basile

Università Cattolica del Sacro Cuore, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RRRiccardo Rinaldi
Riccardo Rinaldi
MBMattia Basile
Mattia Basile
CSCarmine Salzillo
Carmine Salzillo
DGDomenico Luca Grieco
Domenico Luca Grieco
ACAndrea Caffè
Andrea Caffè
OGon behalf of the Gemelli against COVID Group
on behalf of the Gemelli against COVID Group
Background: Cardiovascular sequelae after COVID-19 are frequent. However, the predictors for their occurrence are still unknown. In this study, we aimed to assess whether myocardial injury during COVID-19 hospitalization is associated to CV sequelae and death after hospital discharge. Methods: In this prospective observational study, consecutive patients who were admitted for COVID-19 in a metropolitan COVID-19 hub in Italy, between March 2021 and January 2022, with a ≥ 1 assessment of high sensitivity cardiac troponin I (hs-cTnI) were included in the study, if they were alive at hospital discharge. Myocardial injury was defined as elevation hs-cTnI > 99th percentile of the upper reference limit. The incidence of all-cause mortality and major adverse cardiovascular and cerebrovascular events (MACCE, including cardiovascular death, admission for acute or chronic coronary syndrome, hospitalization for heart failure, and stroke/transient ischemic attack) at follow-up were the primary outcomes. Arrhythmias, inflammatory heart diseases, and/or thrombotic disorders were analyzed as well. Results: Among the 701 COVID-19 survivors (mean age 66.4 ± 14.4 years, 40.2% female), myocardial injury occurred in 75 (10.7%) patients. At a median follow-up of 270 days (IQR 165, 380), all-cause mortality (21.3% vs. 6.1%, p < 0.001), MACCE (25.3% vs. 4.5%, p < 0.001), arrhythmias (9.3% vs. 5.0%, p = 0.034), and inflammatory heart disease (8.0% vs. 1.1%, p < 0.001) were more frequent in patients with myocardial injury compared to those without. At multivariate analysis, myocardial injury (HR 1.95 [95% CI:1.05–3.61]), age (HR 1.09 [95% CI:1.06–1.12]), and chronic kidney disease (HR 2.63 [95% CI:1.33–5.21]) were independent predictors of death. Myocardial injury (HR 3.92 [95% CI:2.07–7.42]), age (HR 1.05 [95% CI:1.02–1.08]), and diabetes (HR 2.35 [95% CI:1.25–4.43]) were independent predictors of MACCE. Conclusion: In COVID-19 survivors, myocardial injury during the hospital stay portends a higher risk of mortality and cardiovascular sequelae and could be considered for the risk stratification of COVID-19 sequelae in patients who are successfully discharged.

20 May 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
MBMattia Basile
Mattia Basile
AGAntonio GómEz‐Menchero
Antonio GómEz‐Menchero
BRBorja Rivero-Santana
Borja Rivero-Santana
Ignacio J. Amat-SantosIgnacio J. Amat-Santos
Ignacio J. Amat-Santos
SJSantiago JiménEz‐Valero
Santiago JiménEz‐Valero
AJAlfonso Jurado-Roman
Alfonso Jurado-Roman

25 March 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
MBMattia Basile
Mattia Basile
CSCarmine Salzillo
Carmine Salzillo
EBEmiliano Bianchini
Emiliano Bianchini
FBFrancesco Bianchini
Francesco Bianchini
AJAlfonso Jurado-Roman
Alfonso Jurado-Roman
GSGregory A. Sgueglia
Gregory A. Sgueglia

17 February 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
MLMarco Lombardi
Marco Lombardi
MBMattia Basile
Mattia Basile
AJAlfonso Jurado-Roman
Alfonso Jurado-Roman
GOGiovanni Occhipinti
Giovanni Occhipinti
JEJavier Escaned
Javier Escaned
IPitalo porto
italo porto
Background: Secondary mitral regurgitation is associated with adverse clinical outcomes and cardiac remodeling. While transcatheter edge‐to‐edge repair (TEER) improves symptoms and prognosis in selected patients, its effects on cardiac remodeling remain debated. This systematic review and meta‐analysis aimed to evaluate the impact of TEER on echocardiographic indices of cardiac remodeling. Methods: PubMed, Scopus, and Cochrane Library were used to identify relevant studies assessing echocardiographic changes before and after TEER. Outcomes of interest were left ventricular (LV) ejection fraction, global longitudinal strain, LV end‐diastolic and end‐systolic volumes and LV end‐diastolic and end‐systolic diameter, tricuspid annular plane systolic excursion, pulmonary artery systolic pressure, and left atrial end‐systolic volume. Results: Forty‐two studies (3987 patients) were included. TEER was associated with a significant increase in LV ejection fraction (mean difference [MD], 1.51% [95% CI, 0.47–2.55]), without significant improvement in global longitudinal strain. Significant LV remodeling was observed, with reductions in LV end‐diastolic volume (standardized MD, −0.26 [95% CI, −0.37 to −0.14]), LV end‐systolic volume (standardized MD, −0.21 [95% CI, −0.30 to −0.12]), LV end‐diastolic diameter (MD, −2.35 mm [95% CI, −3.66 to −1.04]) and left ventricular end‐systolic diameter (MD, −2.30 mm [95% CI, −3.86 to −0.74). TEER also improved right ventricular function (tricuspid annular plane systolic excursion [MD, 1.29 mm [95% CI, 0.60–1.97]) and reduced pulmonary artery systolic pressure (MD, −6.75 mm Hg [95% CI, −8.53 to −4.97). No significant improvement in left atrial end‐systolic volume was detected. Conclusions: Available evidence suggests that TEER promotes significant cardiac remodeling in patients with secondary mitral regurgitation.

8 October 2026 in International Journal of Cardiology
Verified
Journal Article
Closed access
MBMattia Basile
Mattia Basile
JHJavier Gómez Herrero
Javier Gómez Herrero
AGAlejandro Lara García
Alejandro Lara García
JHJosé Maria de la Torre Hernández
José Maria de la Torre Hernández
FAFernando Alfonso
Fernando Alfonso
ARAlfonso Jurado Román
Alfonso Jurado Román

6 July 2026 in European Heart Journal - Valvular and Structural Heart Disease
Verified
Journal Article
Open access
MBMattia Basile
Mattia Basile
MMMiguel A Martín-Arena
Miguel A Martín-Arena
JZJon Zubiaur-Zamacola
Jon Zubiaur-Zamacola
ICIgnacio Cruz-Gonzalez
Ignacio Cruz-Gonzalez
BRBorja Rivero-Santana
Borja Rivero-Santana
GGGuillermo Galeote
Guillermo Galeote
Background and Aims: Left atrial appendage occlusion (LAAO) is an established alternative for stroke prevention in patients with atrial fibrillation who are unsuitable for long-term anticoagulation. Although device embolization is rare, it represents a potentially catastrophic complication. Robust contemporary data on its incidence, timing, determinants, and clinical consequences are limited. To provide contemporary, comprehensive estimates of device embolization after percutaneous LAAO and to identify factors associated with embolization risk and related mortality. Methods: We conducted a systematic review and meta-analysis of studies reporting device embolization after LAAO, as well as embolization-related mortality. Random-effects models were applied to estimate pooled embolization incidence and case-fatality rates. Subgroup analyses were performed by device type and device family. Exploratory meta-regression assessed sources of heterogeneity, including publication year and study sample size. Results: Seventy-three studies, including seventy observational studies and three randomized controlled trials, involving 97 316 patients, were analysed. The pooled embolization incidence was .31% [95% confidence interval (CI) .19%–.50%]. Among studies reporting embolization timing, 80% of events occurred within 24 h of implantation. Larger sample size and more recent publication year were independently associated with lower embolization risk. Device-specific incidence was lowest for Watchman FLX (.02%) and Watchman 2.5 (.12%), and higher for Amplatzer Cardiac Plug (1.02%) and Amulet (.43%). Embolization-related mortality was 10.61% (95% CI 4.98%–21.16%), with no evidence of temporal improvement. Conclusions: Device embolization after LAAO is infrequent and has declined substantially over time, likely reflecting technological advances and procedural experience. However, when embolization occurs, it remains associated with high mortality, underscoring the importance of careful device selection and optimized implantation strategies.